Sign In
Buy TLTFF
$0.166
+0.0001 (+0.0602%)
At Close: Jun 23, 2026
Theralase Technologies Inc. (TLTFF) Q1 2025 Earnings Call Transcript
12:57pm, Monday, 09'th Jun 2025
Theralase Technologies Inc. (OTCQX:TLTFF) Q1 2025 Earnings Conference Call June 9, 2025 11:00 AM ET Company Participants Kristina Hachey - CFO & Director Matthew Perraton - Corporate Participant Roger
Theralase Annual General Meeting
07:00am, Thursday, 05'th Jun 2025
Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light,
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
04:30pm, Thursday, 29'th May 2025
Radiation-Activated Rutherrin(R) Versus Radiation Alone in Preclinical Cancer Models to be Presented at ASTRO 2025 This Press Release removes references to preclinical data that has not yet been prese
Theralase to Present Groundbreaking Research at ASTRO 2025
07:00am, Wednesday, 28'th May 2025
Radiation-Activated Rutherrin(R) Shown to Be 100 Times More Effective Than Radiation Alone in Preclinical Cancer Models Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Theralase® Technologies Inc
Theralase Provides Corporate Update
07:00am, Tuesday, 20'th May 2025
Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the
Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
07:00am, Monday, 05'th May 2025
Toronto, Ontario--(Newsfile Corp. - May 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the r
Theralase Discovers New Mechanism of Action of Lead Drug
07:00am, Monday, 28'th Apr 2025
Theralase(R) Has Discovered a New Mechanism of Action in Its War on Cancer; Specifically, Ruvidar's(TM) Ability to Inhibit DeUbiquitinating Enzymes, an Important Class of Enzymes Which Have Been Linke
Theralase(R) Closes Non-Brokered Private Placement
04:22pm, Monday, 14'th Apr 2025
Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to th
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
07:00am, Thursday, 10'th Apr 2025
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto,
Ruvidar Demonstrates 7 Year Complete Response
07:00am, Monday, 07'th Apr 2025
Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) Demonstrates 7 Year Complete Response Toronto, Ontario--(News
Ruvidar Effective in the Treatment of Herpes
07:00am, Monday, 24'th Mar 2025
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(
Theralase Technologies Inc. (TLTFF) Q4 2024 Earnings Call Transcript
01:51pm, Wednesday, 19'th Mar 2025
Theralase Technologies Inc. (OTCQX:TLTFF) Q4 2024 Earnings Conference Call March 19, 2025 11:00 AM ET Company Participants Matthew Perraton - Chairman of the Board Kristina Hachey - Chief Financial Of
Theralase(R) Releases 2024 Annual Financial Statements
07:00am, Wednesday, 12'th Mar 2025
Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to th
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
04:15pm, Tuesday, 25'th Feb 2025
Rutherrin(R), when combined with a common diabetic drug and radiation, was able to effectively destroy Non-Hodgkin's Lymphoma in an animal model. Toronto, Ontario--(Newsfile Corp. - February 25, 2025)
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
12:30pm, Thursday, 13'th Feb 2025
This Press Release updates numerical list in reference section Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of
